Kyowa Hakko Kogyo Maps Three-Year Plan For Kidney Disease Role
This article was originally published in PharmAsia News
Kyowa Hakko Kogyo of Japan has mapped out a three-year plan designed to give it a greater presence in the market for treating kidney diseases. The plan envisions increased sales of its medical division by 10 percent during the run of the plan. Particular attention is to be given to a drug for treating renal anemia, developed by Kirin Pharma and acquired by Kyowa last fall in a merger to be completed in October. To increase sales, Kyowa plans to increase its sales force to about 1,400 representatives. The plan also calls for working with Kirin to bring antibody drugs to market. (Click here for more - a subscription may be required
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?